Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Progesterone intravenous - BHR Pharma

Drug Profile

Progesterone intravenous - BHR Pharma

Alternative Names: BHR-100

Latest Information Update: 14 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BHR Pharma
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Apoptosis inhibitors; GABA modulators; Glutamate antagonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Lipid peroxidation inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 01 Mar 2014 BHR Pharma complete the global phase III SyNAPSe trial for Brain injuries in USA, Argentina, China, Europe, Israel, Malaysia, Russia, Singapore, Taiwan and Thailand (NCT01143064)
  • 03 Sep 2013 BHR Pharma completes enrolment in the global phase III SyNAPSe trial for Brain injuries (NCT01143064)
  • 22 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top